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Abstract The objectives of this study are to assess the
efﬁcacy and safety of frovatriptan, and rizatriptan in the
subgroup of women with menstrually related migraine of a
multicenter, randomized, double blind, cross-over study.
Each patient received frovatriptan 2.5 mg or rizatriptan
10 mg in a randomized sequence: after treating 3 episodes
of migraine in not more than 3 months with the ﬁrst
treatment, the patient had to switch to the other treatment.
Menstrually related migraine was deﬁned according to the
criteria listed in the Appendix of the last IHS Classiﬁcation
of Headache disorders. 99 out of the 125 patients included
in the intention-to-treat analysis of the main study were of a
female gender: 93 had regular menstrual cycles and were,
thus, included in this analysis. A total of 49 attacks clas-
siﬁed as menstrually related migraine were treated with
frovatriptan and 59 with rizatriptan. Rate of pain relief at
2 h was 58% for frovatriptan and 64% for rizatriptan
(p = NS), while rate of pain free at 2 h was 31 and 34%
(p = NS), respectively. At 24 h, 67 and 81% of frova-
triptan-treated, and 61 and 74% of rizatriptan-treated
patients were pain free and had pain relief, respectively
(p = NS). Recurrence at 24 h was signiﬁcantly (p\0.01)
lower with frovatriptan (10 vs. 32% rizatriptan). Frova-
triptan was as effective as rizatriptan in the immediate
treatment of menstrually related migraine attacks while
showing a favorable sustained effect with a lower rate of
migraine recurrence. These results need to be conﬁrmed by
randomized, double-blind, prospective, large clinical trials.
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Introduction
The high prevalence of migraine in the female population
is well established: approximately one-quarter of women
experience migraine at some time in their lives and over
half of them report an association between menstruation
and migraine [1]. Menstrually related migraine leads to
substantial disability and attacks are more severe, longer in
duration, and have a poorer response to analgesics than
episodes occurring in other time of the month [2]. Drug
prophylaxis may be useful for menstrual migraine [3].
Triptans have proved to be the most effective acute
treatment of migraine headaches and are preferable for
menstrual migraine in view of its difﬁcult-to-treat nature
[4, 5]. Prospective, randomized, controlled trials as well as
retrospective analyses and open label studies support the
use of triptans as acute therapy for menstrual migraine [5].
Sumatriptan, the ﬁrst triptan to be marketed, has been
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DOI 10.1007/s10194-011-0366-9shown to be well tolerated and effective in providing pain
relief in menstrually associated migraine when adminis-
tered in the mild pain phase, also in combination with
analgesics [6–12]. Second generation triptans such as
zolmitriptan [13–15], naratriptan [16], rizatriptan [17–21]
and more recently almotriptan [14, 22] and frovatriptan
[23] have been also successfully tested: the different
pharmacokinetic and pharmacodynamic features of these
triptans as respect to sumatriptan potentially render them
particularly suitable for treating menstrual migraine. Fol-
lowing extensive evidence from prospective, double-blind,
randomized, controlled studies, recent guidelines now
recommend sumatriptan 50 and 100 mg or rizatriptan
10 mg for acute treatment of menstrually related migraine,
and frovatriptan 2.5 mg or naratriptan 1 mg twice daily for
preventive treatment of this condition [4, 24].
The preventive efﬁcacy of frovatriptan has been largely
demonstrated by randomized, double-blind, placebo con-
trolled or open label studies [25–29]. Frovatriptan has been
proved to be effective also in the acute management of
menstrual migraine [30], including oral-contraceptive-
induced menstrual migraine a subtype of menstrual
migraine caused by estrogen withdrawal occurring during
the week of pill suspension [31]. More recently, in an open-
label post-marketing surveillance study conducted in
women with migraine associated with menses, acute
frovatriptan treatment improved patients’ ratings of treat-
ment effectiveness and tolerability as compared to previ-
ously used triptans [32].
Since there are presently no studies comparing the
efﬁcacy of frovatriptan with that of another second gen-
eration triptan in menstrual migraineurs, an analysis of a
recently published double-blind, randomized, cross-over
study, comparing the efﬁcacy of frovatriptan versus riza-
triptan [33] has been carried out in a subgroup of women
with menstrually related migraine and is reported in the
present paper.
Methods
Study population
Subjects of both genders, aged 18–65 years, with a current
history of migraine with or without aura, according to
International Headache Society (IHS) 2004 criteria, and
with at least one, but not more than 6 migraine attacks per
month for 6 months prior to entering the study, were
enrolled in the main study [33, 34]. In the present analysis,
women with menstrually related migraine were selected.
This condition was deﬁned according to IHS criteria as
migraine without aura attacks in a menstruating woman,
occurring on day 1 ± 2 (namely days -2t o?3) of
menstruation in at least 2 out of 3 menstrual cycles and
additionally at other times of the cycle [34].
Main exclusion criteria were: (a) uncontrolled hyper-
tension; (b) ischemic heart disease; (c) cardiac arrhyth-
mias or symptomatic Wolff–Parkinson–White syndrome;
(d) previous stroke or transient ischemic attack; (e) severe
liver or renal impairment; (f) any other severe or disabling
medical condition; (g) history of alcohol or analgesic or
psychotropic drug abuse; (h) known hypersensitivity to
study drugs; (i) previously demonstrated inadequate
response to at least two triptans; (j) current use of pro-
pranolol or ergothamine (and its derivatives) as a prophy-
lactic agent; (k) current use or use in the previous 2 weeks
of MAO-inhibitors; (l) use of either test medication to treat
any one of the last three episodes of migraine; and
(m) other headaches that have been lasting for more than
6 days. Pregnant women and breast-feeding mothers were
excluded as well, while women with childbearing potential
but not practicing an effective method of birth control were
to be submitted to a pregnancy test, if clinically indicated.
All patients gave written informed consent prior to their
inclusion into the study. The study was approved by the
Independent Institutional Review Boards of the study
centers.
Study design
Details on the study design are available in a previous
publication [33]. Brieﬂy, this was a multicenter, random-
ized, double blind, cross-over study, including 14 Italian
centers (see Appendix). Each patient received frovatriptan
2.5 mg or rizatriptan 10 mg in a randomized sequence:
after treating 3 episodes of migraine in not more than
3 months with the ﬁrst treatment, the patient had to switch
to the other treatment. Subjects were encouraged to treat 1
to 3 attacks for a maximum period of 6 months and to visit
the center three times. Subjects having no migraine epi-
sodes during one of the two observation periods were
excluded from the study.
During the randomization visit, after signing written
informed consent, subjects provided a medical, treatment
and migraine history. A physical and neurological exami-
nation and pregnancy test (if appropriate) were performed.
Blood pressure and heart rate were measured for all the
subjects. The degree of migraine-associated disability
(MIDAS questionnaire) was also completed. At the end of
the visit, a headache diary documenting characteristics of
headache pain (including its relation with menses) and
associated symptoms was dispensed with study medication.
Subjects were instructed to treat at least 3 migraine epi-
sodes occurring in not more than 3 months and to come for
the second visit. On this occasion, use of concomitant
medications and occurrence of adverse events (from diary)
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123were checked, blood pressure and heart rate were recorded,
and a pregnancy test performed, if deemed necessary. The
same procedures were carried out at the end of the second
study treatment period or at the early withdrawal visit.
Patients were instructed to take one dose of study
medication as early as possible after the onset of migraine
attack. If insufﬁcient relief had been obtained after 2 h,
patients were allowed to take a second dose of study
medication, with a maximum daily intake of two doses. In
case of insufﬁcient relief 1 h after the intake of the second
dose of the study medication, patients were allowed to take
a rescue medication. Alternate rescue medication could not
include triptans, or contain ergotamine or its derivatives, or
propranolol.
Data analysis
This analysis was carried out in all normally menstruating
women randomized to any of the two treatment sequences,
having not positively refused to receive either study treat-
ment and having treated at least one episode of men-
strual migraine with both medications (intention-to-treat
population).
The study endpoints were deﬁned [34], as (a) the
number of pain relief episodes at 2 h (a decrease in
migraine intensity from severe or moderate to mild or none
at 2 h); (b) the number of pain free episodes at 2 h (absence
of migraine episodes at 2 h after intake of one dose of
study drug); (c) the number of pain free episodes at 24 h
(absence of migraine episodes at 24 h); (d) the number of
pain relief episodes at 24 h (a decrease in migraine inten-
sity from severe or moderate to mild or none at 24 h); and
(e) recurrence within 24 h (episodes pain free at 2 h and
headache of any severity returns within 24 h or intake of a
second study drug or rescue medication). Consistency of
response (responders in 2 and 3 out of 3 attacks) was also
assessed for each study endpoint.
Changes in headache intensity from baseline after 2, 4,
24 and 48 h from study drug intake, were also evaluated.
Analysis of pain free episodes was carried out also
according to baseline headache intensity (mild, moderate
or severe). Frequency of pain free and pain relief episodes
was also assessed and compared between menstrually and
non-menstrually related migraine attacks.
Continuous variables were summarized by computing
average values and standard deviation (SD), while cate-
gorical variables by computing the absolute value and the
frequency (as percentage). Endpoints were compared
between groups by generalized estimating equation analy-
sis. Kaplan–Meyer curves for cumulative hazard of recur-
rence over the 48 h were also drawn. p value refers to the
statistical signiﬁcance of between treatment difference.
The level of statistical signiﬁcance was kept at 0.05
throughout the whole study.
Results
Overall 125 subjects formed the main study population
[29]: 99 of them were of a female gender and 93 had a
regular menstrual cycle and were, thus, included in this
analysis.
Main demographic and clinical characteristics of the
patients of the whole study population and of the subgroup
of women with menstrually related migraine are reported in
Table 1. As compared to the main study population, the
women of this analysis were less tall (p\0.01 between
groups) and thinner (p\0.01), and had a higher MIDAS
score (p\0.05). The proportion of patients suffering from
attacks lasting more than 2 days was larger in the group of
women with menstrual migraine (25 women vs. 1 woman
with non-menstrual migraine, p\0.05).
Overall efﬁcacy of study drugs
49 attacks (17% of all attacks) classiﬁed as menstrually
related migraine were treated with frovatriptan and 59
(21%) with rizatriptan.
The proportion of pain relief episodes was similar
(p = NS) between frovatriptan and rizatriptan at 2 h (58
vs. 64%) and at 24 h (81 vs. 74%). Also, the rate of pain
free episodes at 2 and 24 h did not differ between the two
Table 1 Demographic and
clinical baseline data of the 125
patients of the main study (33)
and of the subgroup of 93
women with menstrually related
migraine
Data are shown as mean (±SD),
or absolute (n) and relative
frequency (%)
Main study
n = 125
Menstruating Women
n = 93
p
Age (years, means ± SD) 37 ± 93 6 ± 9N S
Height (cm, means ± SD) 167 ± 9 163 ± 7 \0.01
Weight (kg, means ± SD) 64 ± 13 59 ± 8 \0.01
Age at onset of migraine (years, means ± SD) 16 ± 71 6 ± 6N S
Migraine attack duration[2 days (n, %) 26 (21) 25 (28) NS
MIDAS score (means ± SD) 22 ± 15 26 ± 17 \0.05
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123treatment groups (31 and 67% frovatriptan vs. 34 and 61%
rizatriptan; p = NS for both) (Table 2).
The rate of migraine recurrence after 24 h was signiﬁ-
cantly (p\0.01) lower under frovatriptan (10%) than
under rizatriptan (32%). Also, the cumulative hazard
of recurrence during the follow-up was signiﬁcantly
(p\0.01) lower under frovatriptan (Fig. 1).
Consistency of response never resulted signiﬁcantly
different between the two groups, even for recurrences,
probably due to the low number of subjects available for
this sub-analysis (Table 3).
Efﬁcacy of study drugs according to baseline migraine
intensity
Most of the treated attacks had a moderate or severe
intensity at baseline. When rate of pain free episodes at 2
and 24 h was compared between treatments according to
baseline migraine severity, frovatriptan was superior to
rizatriptan at 2 h and at 24 h for treatment of moderate to
severe attacks, with a statistically signiﬁcant between
treatment difference at 24 h (p\0.01, Table 4).
Changes in migraine intensity
During the 48 h observation period, migraine intensity was
progressively reduced by both drugs, but in a signiﬁcantly
larger degree with frovatriptan, particularly between 24 and
48 h (Fig. 2).
Menstrually and non-menstrually related migraine
attacks
Table 5 shows the number and proportion of pain free and
pain relief-episodes at 2 and 24 h after frovatriptan intake
for the 49 attacks related to and for the 233 attacks unre-
lated to the menstrual cycle. Frequency of pain relief at 2
and 24 h was 58 and 81% in menstrually related attacks
and 54 and 87% in non-menstrually related attacks, with no
statistically signiﬁcant difference between the two types of
Table 2 Main study endpoints in the two study treatment groups
Frovatriptan Rizatriptan p
Pain relief episodes at 2 h 25 (58) 27 (64) NS
Pain free episodes at 2 h 15 (31) 20 (34) NS
Pain relief episodes at 24 h 35 (81) 31 (74) NS
Pain free episodes at 24 h 33 (67) 36 (61) NS
Recurrent episodes at 24 h 5 (10) 19 (32) \0.01
Data are reported as absolute (n) and relative (%) frequency. P refers
to the statistical signiﬁcance of the difference between the two study
drugs
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Fig. 1 Cumulative hazard of recurrence over the 24 h during
treatment with frovatriptan (continuous line) or rizatriptan (dashed
line) in the 93 women with menstrually related migraine included in
this analysis
Table 3 Results of consistency analysis in the two study treatment
groups
Frovatriptan Rizatriptan p
Pain relief episodes at 2 h 19 (76) 20 (74) NS
Pain free episodes at 2 h 11 (73) 16 (80) NS
Pain relief episodes at 24 h 28 (80) 25 (81) NS
Pain free episodes at 24 h 23 (70) 23 (64) NS
Recurrent episodes at 24 h 3 (60) 16 (84) NS
Consistency of was response was deﬁned as responders in 2 and 3 out
of 3 attacks. Data are reported as absolute (n) and relative (%) fre-
quency. p refers to the statistical signiﬁcance of the difference
between the two study drugs
Table 4 Absolute (n) and relative (%) frequency of pain free epi-
sodes at 2 and 24 h according to baseline headache intensity in the
two treatment groups
Frovatriptan Rizatriptan p
Pain free episodes at
2 hours
Mild 3 (20) 8 (40) NS
Moderate-severe 12 (80) 12 (60)
Pain free episodes at
24 hours
Mild 2 (6) 13 (24) \0.01
Moderate-severe 31 (94) 23 (76)
p refers to the statistical signiﬁcance of the difference between the
two study drugs
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123migraine (p = NS). Similarly, the rate of pain free epi-
sodes at 2 and 24 h was 31 and 67% in menstrual migraine
and 33 and 80% in non-menstrual migraine (p = NS).
Discussion
In the present subgroup analysis of a double-blind, ran-
domized, cross-over study, acute treatment of menstrually
related migraine with frovatriptan and rizatriptan was
associated with a similar immediate effect, as showed by
similar proportions of pain relief and of pain free episodes
at 2 and 24 h between the two drugs. However, frovatriptan
showed signiﬁcantly lower rates of headache recurrence
over the 24 h than rizatriptan, this indicating a better sus-
tained effect which can be explained by differences in
pharmacological features of the two triptans. As a matter of
fact, rizatriptan has a slightly shorter time to maximum
concentration than frovatriptan, but the latter has a longer
half-life (25–26 h vs. 2–3 h of rizatriptan), which might
explain why frovatriptan, unlike rizatriptan, greatly
reduced the risk of migraine recurrence [35–37].
The study provides also two important additional results,
which are worthy being discussed. First, differences in drug
efﬁcacy were observed as a function of baseline migraine
attack severity. In the women with migraine attacks of a
moderate-severe intensity at baseline, the rate of pain free
episodes at 24 h was signiﬁcantly larger under frovatriptan.
This is particularly relevant, considering that the subgroup
of women with menstrually related migraine had a more
disabling form of migraine as compared to the main study
group, as conﬁrmed by a signiﬁcantly high MIDAS score
and a larger proportion of patients with attacks of longer
duration. Second, reduction in migraine intensity during
the observation period was larger under frovatriptan, from
24 to 48 h after the onset of migraine attack and starting
treatment, this conﬁrming the more sustained pain relief
effect of frovatriptan than rizatriptan.
This is the ﬁrst study directly comparing the efﬁcacy of
frovatriptan as acute treatment of menstrually related
migraine versus another triptan. Our study and a compar-
ison study between almotriptan and rizatriptan [14], are the
only two available head-to-head double-blind, randomized
studies comparing the efﬁcacy of two triptans in menstrual
migraine. Though both studies share the limitations of
subgroup analyses, they are useful because no such pro-
spective studies on triptans in menstrual migraine have yet
been carried out. Results of our study adds to the evidence
of previous randomized, placebo controlled or open label
studies proving the efﬁcacy of frovatriptan as intermittent
preventive [25–29] or acute treatment of menstrual
migraine [30–32]. In published reports, prophylactic
treatment with frovatriptan, started 2 days before the
expected onset of headache and continued for 6 days, was
always superior to placebo in reducing the frequency of
menstrual migraine. A randomized, double-blind, placebo
controlled study involving 410 women showed a headache
incidence of only 8% when frovatriptan was given at
dosage of 2.5 mg twice-daily and of 31% when given once-
daily, while the incidence was 58% under placebo [26]. A
post-hoc analysis of a randomized, double-blind, placebo
controlled study in a population of 179 women experi-
encing menstrual migraine showed a signiﬁcantly less
prevalence of menstrual migraine with frovatriptan 2.5 mg
twice (38%) or once-daily (51%) than with placebo (67%)
[27]. These latter results are in line with those of a previous
randomized, double-blind, placebo-controlled study of the
same authors carried out in 546 women migraineurs [28].
Concerning treatment of the acute attack, in a 6-month
open label study frovatriptan was given at 2.5 mg dose to
151 menstrual subjects for 2,439 migraine attacks, 659 of
which occurring during a menstrual period [30]. Migraine
relief within the 24 h was achieved for 82% of menstrual
-2,0
-1,8
-1,6
-1,4
-1,2
-1,0
-0,8
-0,6
2 4 24 48
H
e
a
d
a
c
h
e
 
i
n
t
e
n
s
i
t
y
 
(
c
h
a
n
g
e
 
v
s
.
 
b
a
s
e
l
i
n
e
) Hours post-dose
p<0.05
Fig. 2 Changes in migraine intensity from baseline during treatment
with frovatriptan (continuous line) or rizatriptan (dashed line) in the
93 women with menstrually related migraine included in this analysis
Table 5 Absolute (n) and relative (%) frequency of pain free and
pain relief episodes at 2 and 24 h in menstrually (n = 49) and non-
menstrually related (n = 233) migraine attacks treated with frova-
triptan. p refers to the statistical signiﬁcance of the difference between
the two types of migraine attacks
Menstrually
related
migraine
Non-menstrually
related migraine
p
Pain relief episodes at 2 h 25 (58) 100 (54) NS
Pain free episodes at 2 h 15 (31) 77 (33) NS
Pain relief episodes at 24 h 35 (81) 159 (87) NS
Pain free episodes at 24 h 33 (67) 184 (80) NS
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123attacks, a proportion which was similar to that observed for
non-menstrual attacks (87%). In an open-label uncontrolled
study, including 20 women with a history of oral contra-
ceptive-induced menstrual migraine, pain relief was
reported in 55% of women 2 h after drug intake (58% in
our study), while 10% of subjects were pain free after 2 h
(31% in our study), 35% after 4 h and 60% after 24 h (67%
in our study) [31]. Migraine intensity signiﬁcantly
decreased after 24 h by 1.6, an extent similar to that
observed in our study at the same time point (1.5).
Evidence as acute treatment of menstrual migraine is
available also for rizatriptan. In the published studies, rate
of pain relief episodes at 2 h with rizatriptan was 64–78%
(18–21), rate of pain free episodes at 2 h was 50% [20],
while pain relief at 24 h was 63% [17] and pain free at 24 h
was 32–34% [17, 20]: in our study, the corresponding
ﬁgures for rizatriptan were very similar with respect to pain
relief at 2 h (64%), slightly lower for pain free at 2 h (34%)
and slightly higher for pain relief and pain free at 24 h (74
and 61%, respectively). No data on frequency of recur-
rences are available from previous studies on rizatriptan.
Differences between our results and those of previous
studies might be attributed to differences in study design
and patients’ characteristics: in particular, in some heter-
ogeneity in the deﬁnition of menstrual migraine is evident
among studies.
Conclusions
The present analysis of data from a multicenter, random-
ized, double-blind, head-to-head study suggests that
frovatriptan and rizatriptan are similarly effective in the
immediate treatment of women with menstrually related
migraine. The study provides the ﬁrst evidence that
frovatriptan is superior to rizatriptan in reducing recurrence
in menstrual migraine patients. The good sustained effect
of frovatriptan shown in our study, seems to support indi-
cation of frovatriptan not only, as previously suggested, for
preventive treatment of menstrual migraine [25–29], but
also for managing the acute attack. The sustained analgesic
effect of frovatriptan, supported by the lesser risk of
recurrence may suggest the use of this drug for those
patients with long-duration or recurrent migraine attacks
[38, 39]. Caution must be taken when the drug is used
within the same month for treating migraine attacks
occurring during menses and outside the menstrual period,
because of the risk of medication-overuse-headache, a risk
which is, however, common to all triptans used for men-
strual-migraine prophylaxis or treatment.
Given the retrospective design of our study, its results
need to be conﬁrmed by subsequent double-blind, ran-
domized, prospective, large clinical trials.
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